Charles River Laboratories International Inc
NYSE:CRL
Charles River Laboratories International Inc
NYSE:CRL
Price:
228.41 USD
0.13%
Market Closed
Updated:
May 14, 2024
P/E
Price to Earnings
Price to Earnings
26.8
Current
26.8
Median
31.1
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=26.8
Market Cap
/
11.8B
Net Income
438.8m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Charles River Laboratories International Inc
NYSE:CRL
|
11.8B USD | 26.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
228.4B USD | 38.1 | |
| US |
|
Danaher Corp
NYSE:DHR
|
186.5B USD | 23.1 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
43.2B USD | 34.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41.7B USD | 30.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.2B CHF | 56.9 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 64.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
31.2B USD | 40.1 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.1B USD | 46 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
25.6B USD | 37.5 | |
| US |
|
Waters Corp
NYSE:WAT
|
20.6B USD | 34.1 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
20.5
2-Years Forward
P/E
18.2
3-Years Forward
P/E
16.4
You don't have any saved screeners yet
